Serum visfatin level in obese Egyptian children and adolescents and its relation with metabolic syndrome. Issue 2 (December 2015)

• Record Type: Journal Article
• Authors: Anwar, Ghada M.; Motawei, Ayat A.; Ibrahim, Amany; Galal, Ashraf; Salama, Hassan M.; Aly, Azza A.; Moustafa, Eman A.
• Is Part Of: Medical research journal. Volume 14:Issue 2(2015:Dec.)
• Publication Date: 2015-12
• Subjects: Medicine -- Research -- Periodicals; 610.7205
• DOI: 10.1097/01.MJX.0000472995.93483.08
• Languages: English
• ISSNs: 2090-6250

Abstract

Abstract : Objective: We aimed to study visfatin level in obesity and its relation with metabolic syndrome (MS). Patients and methods: This case–control study included 42 obese children and adolescents and 39 age-matched and sex-matched nonobese children who served as controls. Full medical examination and anthropometric measurements were carried out. Fasting serum total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, blood sugar, insulin, and visfatin were measured. Homeostasis model assessment for insulin resistance (HOMA-IR) was calculated. Results: Fasting serum visfatin level was significantly higher in obese children and adolescents compared with controls (8.7±2.8 vs. 3.3±2.3 ng/ml, P =0.001). Visfatin showed significant positive correlations with waist circumference ( P <0.001), systolic blood pressure ( P =0.001), diastolic blood pressure ( P =0.01), and fasting blood glucose ( P =0.001). Visfatin was significantly higher in obese patients with MS than in patients without MS (10.03±3.2 vs. 7.8±2.2 ng/ml, P =0.02). Conclusion: Visfatin elevated in obese children. Visfatin might be used as a predictor test for the existence of MS in obese children.